Details for Patent: 5,660,846

Title:	Methods and apparatus for the delivery of solid drug compositions
Abstract:	The invention features an implantable device for the automatic delivery of an active ingredient according to an adjustable delivery profile. The device includes a housing; a reservoir operatively connected to the housing and arranged to store a solid composition including the active ingredient; an actuator arranged within the housing to move the solid composition from the reservoir to a transit area, wherein the solid composition exits the housing at the transit area; a controller that acts on the actuator to adjust movement of the solid composition out of the housing according to the adjustable delivery profile; and a power source arranged to provide energy to the actuator and the controller. The solid composition can be an elongate, solid composition comprising a drug, and up to 90% of a carrier, wherein the composition has a cross-section of less than 0.5 mm, and wherein the drug and the carrier are selected and compounded in a proportion such that the drug is immediately released from the carrier upon contact with a liquid.
Inventor(s):	Cheikh; Roland Cherif (Issy-les-Moulineaux, FR)
Assignee:	Societe de Conseils de Recherches et d'Applications Scientifiques (Paris, FR)
Filing Date:	Jun 02, 1995
Application Number:	08/459,514
Claims:	1. An elongate, anhydrous, homogeneous, solid drug composition, said composition comprising a drug, and up to 90% of a carrier, wherein said composition comprises a maximum cross-sectional diameter of less than 0.5 mm, and wherein said drug and said carrier are selected and compounded in a proportion such that said drug is dispersed from said solid, homogeneous composition upon contact with bodily fluids and is distributed within the patient's blood stream to achieve a blood level concentration of said drug that is within 50 percent of a blood level concentration of said drug when administered in a liquid formulation, as measured over time after any initial peaks in concentration have stabilized. 2. A composition of claim 1, wherein said composition is in the form of a filament. 3. A composition of claim 1, wherein said drug is insulin. 4. A composition of claim 1, wherein said carrier is water-soluble. 5. A composition of claim 4, wherein said carrier is selected from the group consisting of cellulose, hydroxy propyl methylcellulose, carboxy methylcellulose, hydroxy ethylcellulose, hyaluronic acid, dextrose, mannose, glucose, or gelatin. 6. A composition of claim 1, wherein said composition has a surface area to drug ratio of at least 10 square millimeters per milligram of the drug. 7. A composition of claim 1, wherein said composition comprises at least 30 percent, by weight, of said drug and up to 70 percent, by weight, of said carrier. 8. A composition of claim 1, wherein said composition comprises at least 50 percent, by weight, of said drug and up to 50 percent, by weight, of said carrier. 9. A composition of claim 1, wherein said drug is a polypeptide. 10. An elongate, anhydrous, solid drug composition of claim 1, said composition consisting essentially of at least 10 percent, by weight, of said drug and up to 90 percent, by weight, of said carrier. 11. A composition of claim 10, wherein said composition consists essentially of at least 30 percent, by weight, of said drug and up to 70 percent, by weight, of said carrier. 12. A composition of claim 7, wherein said composition consists essentially of at least 50 percent, by weight, of said drug and up to 50 percent, by weight, of said carrier. 13. A composition of claim 7, wherein said drug is a polypeptide.